Navidea biopharmaceuticals announces issuance of u.s. patent for diagnosis and treatment of viral infections

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the u.s. patent and trademark office (“uspto”) issued to navidea u.s. patent 11,007,272, entitled “compounds and methods for diagnosis and treatment of viral infections,” with protection to october 7, 2037. this patent protects the use of navidea's mannosylated de
NAVB Ratings Summary
NAVB Quant Ranking